Clinical Trials Logo

EBV+ Associated Lymphoma clinical trials

View clinical trials related to EBV+ Associated Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06391814 Recruiting - Clinical trials for EBV Associated Lymphoma

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

Start date: January 16, 2024
Phase: N/A
Study type: Interventional

Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.

NCT ID: NCT05011058 Recruiting - Clinical trials for EBV-Positive DLBCL, NOS

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

NAVAL-1
Start date: May 28, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

NCT ID: NCT02822495 No longer available - Clinical trials for Stem Cell Transplant Complications

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.

NCT ID: NCT01823718 Active, not recruiting - Clinical trials for EBV Associated Lymphoma

Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes

Start date: February 2007
Phase: Phase 1
Study type: Interventional

Patients patients enrolled in this study have a Lymphoma caused by EBV (after bone marrow transplantation, organ transplantation or patient immunodeficient. They will receive one to three injections of allogenic CTL specific EBV. The purpose of this study is to ensure that these injections can not cause a GVH and to study what the side effects are and to see whether this therapy might help patients with Lymphoma. Immunological monitoring will also be studied.